Glucagon-Like Peptide-1 as a Key Regulator of Lipid and Lipoprotein Metabolism in Fasting and Postprandial States

ISSN: 2212-4063 (Online)
ISSN: 1871-529X (Print)


Volume 14, 3 Issues, 2014


Download PDF Flyer




Cardiovascular & Hematological Disorders-Drug Targets

Formerly: Current Drug Targets - Cardiovascular & Hematological Disorders

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Garry X. Shen
University of Manitoba
Winnipeg, MB
Canada


View Full Editorial Board

Subscribe Purchase Articles Order Reprints


Glucagon-Like Peptide-1 as a Key Regulator of Lipid and Lipoprotein Metabolism in Fasting and Postprandial States

Author(s): Sarah Farr, Jennifer Taher and Khosrow Adeli

Affiliation: Program in Molecular Structure & Function, Research Institute, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, M5G 1X8.

Abstract

Insulin resistance and the metabolic syndrome are associated with fasting and postprandial dyslipidemia. This involves the hepatic and intestinal overproduction of very low density lipoproteins (VLDL) and chylomicron particles, respectively, which give rise to atherogenic remnants upon lipolysis in the circulation. Recently, the insulin secretagogue glucagon-like peptide-1 (GLP-1) has received attention not only as an anti-diabetic therapy for regulating glycaemia, but also as a regulator of lipid and lipoprotein metabolism. In fact, agents that raise endogenous bioactive levels of GLP-1 (dipeptidyl peptidase 4 inhibitors) and agents that directly stimulate GLP-1 receptors (GLP-1 receptor agonists) have been assessed in both preclinical and clinical trials for their ability to modulate plasma lipid parameters. Here we describe current evidence supporting a role for GLP-1 in preventing elevated intestinal chylomicron output and postprandial hypertriglyceridemia – an independent predictor of cardiovascular risk. Furthermore, we examine a role for GLP-1 in regulating fasting hepatic VLDL production and hindering the development of a potentially devastating comorbidity, hepatic steatosis. Possible mechanisms of action of GLP-1 are discussed including a reduction in intestinal absorption of dietary lipid and enhanced hepatic fatty acid oxidation or autophagy. Finally, we discuss the current controversy over whether these effects could occur via direct receptor stimulation or alternative, indirect pathways. We conclude that GLP- 1-based therapies appear promising in the management of diabetic dyslipidemia, and further studies are warranted to elucidate their mechanisms of action in both the intestine and liver.

Keywords: Apolipoprotein, chylomicron, dyslipidemia, glucagon-like peptide-1, hepatic steatosis, insulin resistance, very low density lipoprotein.

Purchase Online Rights and Permissions

  
  



Article Details

Volume: 14
Issue Number: 2
First Page: 126
Last Page: 136
Page Count: 11
DOI: 10.2174/1871529X14666140505125300
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science